PALIPALISADE BIO, INC.vs its industry peers
A metric-by-metric comparison of PALISADE BIO, INC. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PALIThis | $220M#8 | 1.9x#1 | 1.8x#8 | — | — | -16.2%#6 | — | -13.8%#3 | — | — | -31.1%#10 | — |
| SABS | $286M#2 | — | 1.4x#6 | — | -100.0%#8 | 138.9%#1 | — | 6.3%#1 | — | — | -2.3%#7 | — |
| LXEO | $267M#3 | — | 1.1x#5 | 407.7x#10 | — | -1.7%#5 | -16706.0%#10 | -42.5%#9 | — | — | -61.1%#15 | — |
| LCTX | $260M#4 | — | 4.3x#12 | 17.9x#6 | 53.2%#3 | -241.4%#14 | -251.6%#6 | -104.3%#13 | — | — | -43.3%#11 | — |
| ALEC | $256M#5 | — | — | 12.1x#5 | -79.1%#7 | -20.2%#7 | -741.3%#7 | — | — | — | 70.9%#2 | — |
| FATE | $255M#6 | — | 1.9x#9 | 38.4x#8 | -51.2%#6 | 26.8%#3 | -2222.4%#9 | -102.5%#12 | -131.3%#2 | — | 75.7%#1 | — |
| CABA | $306M#1 | — | 1.1x#4 | — | — | -44.9%#11 | — | -59.1%#10 | — | — | -47.4%#12 | — |
| DTIL | $225M#7 | 25.2x#3 | 4.4x#13 | 6.6x#4 | -50.1%#5 | -738.0%#16 | -152.2%#3 | -88.3%#11 | — | — | 20.9%#4 | — |
| IKT | $218M#9 | — | 1.4x#7 | — | -100.0%#8 | -75.4%#12 | — | -31.5%#6 | — | — | -2.8%#8 | — |
| PLX | $216M#10 | 11.7x#2 | 3.0x#10 | 4.1x#3 | -1.2%#4 | -325.2%#15 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | 14.3%#6 | — |
| ARTV | $207M#11 | — | 0.6x#1 | — | -100.0%#8 | -28.3%#8 | — | -24.1%#4 | — | — | 18.2%#5 | — |
| ACOG | $188M#12 | — | 3.6x#11 | 18.4x#7 | — | -39.8%#10 | -221.7%#5 | -39.0%#8 | — | — | 50.4%#3 | — |
| IVVD | $186M#13 | — | 1.0x#3 | 3.5x#2 | 110.5%#1 | 69.1%#2 | -104.0%#2 | -29.0%#5 | — | — | -54.5%#14 | — |
| LIMN | $169M#14 | — | 563.0x#14 | — | — | -187.8%#13 | — | -3395.2%#14 | -170.3%#3 | — | -96.0%#16 | — |
| STRO | $165M#15 | — | — | 1.6x#1 | 65.2%#2 | 15.9%#4 | -154.5%#4 | — | — | — | -3.2%#9 | — |
| TARA | $138M#16 | — | 0.9x#2 | 46.9x#9 | — | -28.7%#9 | -2189.6%#8 | -35.6%#7 | — | — | -49.5%#13 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-05.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice